Pharma investors’ tolerance for 1-size-fits-all dose finding continues to astonish me. In this short video, I put the case for making early-phase trial methodology an issue in the boardroom.
The video features this R Shiny app. Details of the pharmacoeconomic argument made here may be found in my bioRxiv preprint, Costing ‘the’ MTD.